A Phase i Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination with Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma

Jeffrey Meyer, Yull Arriaga, Joselin Anandam, Sirisha Karri, Samira Syed, Udit Verma, Abier Abdelnaby, Grace Raja, Ying Dong, Muhammad Shaalan Beg, Glen Balch

Research output: Contribution to journalArticle

Abstract

Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. Materials and Methods: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab. A standard 3+3 trial designed was used. Results: In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma. One patient at the highest dose level experienced a grade III infusion reaction related to the bavituximab. One tumor demonstrated a complete pathologic response to the combination treatment. Conclusions: Bavituximab is safe in combination with capecitabine and radiation therapy at the doses selected for the study. Further clinical investigation would be necessary to better define the efficacy of this combination. ©

Original languageEnglish (US)
Pages (from-to)972-976
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume41
Issue number10
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Fingerprint

Phosphatidylserines
Adenocarcinoma
Radiotherapy
Clinical Trials
Antibodies
Therapeutics
Capecitabine
bavituximab
Carcinoma
Safety
Neoplasms

Keywords

  • phase I
  • radiation
  • rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A Phase i Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination with Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma. / Meyer, Jeffrey; Arriaga, Yull; Anandam, Joselin; Karri, Sirisha; Syed, Samira; Verma, Udit; Abdelnaby, Abier; Raja, Grace; Dong, Ying; Beg, Muhammad Shaalan; Balch, Glen.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 41, No. 10, 01.10.2018, p. 972-976.

Research output: Contribution to journalArticle

Meyer, Jeffrey ; Arriaga, Yull ; Anandam, Joselin ; Karri, Sirisha ; Syed, Samira ; Verma, Udit ; Abdelnaby, Abier ; Raja, Grace ; Dong, Ying ; Beg, Muhammad Shaalan ; Balch, Glen. / A Phase i Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination with Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2018 ; Vol. 41, No. 10. pp. 972-976.
@article{22633091a00e4925a06bf41cf6c0d6b5,
title = "A Phase i Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination with Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma",
abstract = "Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. Materials and Methods: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab. A standard 3+3 trial designed was used. Results: In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma. One patient at the highest dose level experienced a grade III infusion reaction related to the bavituximab. One tumor demonstrated a complete pathologic response to the combination treatment. Conclusions: Bavituximab is safe in combination with capecitabine and radiation therapy at the doses selected for the study. Further clinical investigation would be necessary to better define the efficacy of this combination. {\circledC}",
keywords = "phase I, radiation, rectal cancer",
author = "Jeffrey Meyer and Yull Arriaga and Joselin Anandam and Sirisha Karri and Samira Syed and Udit Verma and Abier Abdelnaby and Grace Raja and Ying Dong and Beg, {Muhammad Shaalan} and Glen Balch",
year = "2018",
month = "10",
day = "1",
doi = "10.1097/COC.0000000000000401",
language = "English (US)",
volume = "41",
pages = "972--976",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - A Phase i Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination with Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma

AU - Meyer, Jeffrey

AU - Arriaga, Yull

AU - Anandam, Joselin

AU - Karri, Sirisha

AU - Syed, Samira

AU - Verma, Udit

AU - Abdelnaby, Abier

AU - Raja, Grace

AU - Dong, Ying

AU - Beg, Muhammad Shaalan

AU - Balch, Glen

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. Materials and Methods: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab. A standard 3+3 trial designed was used. Results: In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma. One patient at the highest dose level experienced a grade III infusion reaction related to the bavituximab. One tumor demonstrated a complete pathologic response to the combination treatment. Conclusions: Bavituximab is safe in combination with capecitabine and radiation therapy at the doses selected for the study. Further clinical investigation would be necessary to better define the efficacy of this combination. ©

AB - Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. Materials and Methods: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab. A standard 3+3 trial designed was used. Results: In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma. One patient at the highest dose level experienced a grade III infusion reaction related to the bavituximab. One tumor demonstrated a complete pathologic response to the combination treatment. Conclusions: Bavituximab is safe in combination with capecitabine and radiation therapy at the doses selected for the study. Further clinical investigation would be necessary to better define the efficacy of this combination. ©

KW - phase I

KW - radiation

KW - rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85054129995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054129995&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000401

DO - 10.1097/COC.0000000000000401

M3 - Article

VL - 41

SP - 972

EP - 976

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 10

ER -